➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Mallinckrodt
Express Scripts
Merck
Dow

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

ERYTHROMYCIN STEARATE - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for erythromycin stearate and what is the scope of freedom to operate?

Erythromycin stearate is the generic ingredient in eight branded drugs marketed by Bristol, Parke Davis, Warner Chilcott, Arbor Pharms Llc, Ani Pharms Inc, Lederle, Mylan, Purepac Pharm, Watson Labs, Bristol Myers Squibb, Pfizer, and Wyeth Ayerst, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

There are one hundred and three drug master file entries for erythromycin stearate. Two suppliers are listed for this compound.

Drug Prices for ERYTHROMYCIN STEARATE

See drug prices for ERYTHROMYCIN STEARATE

Recent Clinical Trials for ERYTHROMYCIN STEARATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ryerson UniversityN/A
Chr Hansen A/SN/A

See all ERYTHROMYCIN STEARATE clinical trials

Pharmacology for ERYTHROMYCIN STEARATE

US Patents and Regulatory Information for ERYTHROMYCIN STEARATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol BRISTAMYCIN erythromycin stearate TABLET;ORAL 061887-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Parke Davis ERYPAR erythromycin stearate TABLET;ORAL 062032-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Bristol Myers Squibb ETHRIL 500 erythromycin stearate TABLET;ORAL 061605-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs ERYTHROMYCIN STEARATE erythromycin stearate TABLET;ORAL 062121-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Medtronic
Dow
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.